Picture1 20purple 202
Xeno 20square

Xeno Biosciences

Delivering the equivalent of bypass surgery in a safe and effective pill to serve a $300B US market for obesity and related diseases

  • Stage Product In Development
  • Industry Biotechnology
  • Location Somerville, MA, USA
  • Currency USD
  • Founded April 2015
  • Employees 2
  • Incorporation Type C-corp
  • Website xenobiosciences.com

Company Summary

Xeno has a disruptive approach to treating obesity and diabetes that mimics gastric bypass surgery using a simple enteric-coated pill. It induces microbiome changes like the surgery resulting in weight loss as shown both in animals and in pilot human studies. It will also be effective in other co-morbidities. We have completed IND-enabling studies. Proceeds will be used for a Phase I study with both safety and weight loss efficacy endpoints.